Overview
A Phase 2A Trial of MM402 Open-Label Study in Adults with Autism Spectrum Disorder
Description
This study will enroll approximately twenty adults with Autism Spectrum Disorder (ASD) aged 18 to 45 years of age.
This is a single-center, open-label study to evaluate the effects after a single administration of MM402 to adults with ASD.
Eligibility
Inclusion Criteria:
- Diagnosis of ASD per records as confirmed by standard semi-structured interview for Autism diagnosis (eg, Autism Diagnostic Observation Schedule-Second Edition)
- Male or Female aged 18 to 45
- Presents with clinically significant deficits in socialization and communication as determined by Social Responsiveness Scales (SRS-2) ≥66
Exclusion Criteria:
- Has uncorrected abnormalities in eye movement, alignment, or acuity or atypical eye features that could interfere with eye tracking
- First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
- Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
- Any clinically significant unstable illness